Rachel Narozniak, MA

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.

TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.

Patients with cancer continue to find their health care providers “more helpful” in managing physical adverse effects resulting from cancer therapy compared with emotional or mental health AEs.

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Combination CDK4/6 and MEK inhibition was “highly synergistic” in killing pancreatic neuroendocrine tumor cells in vitro and effectively suppressed PNET growth in mice.

In an interview with OncologyLive®, Justin F. Gainor, MD, discusses the impact pralsetinib may have on the RET-altered NSCLC paradigm.

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

The coronavirus disease 2019 pandemic has increased levels of perceived and post-traumatic stress among oncology providers and patients with cancer alike, which suggest a need for psychosocial support resources to promote emotional resilience and reduce the risk of post-traumatic stress in patients on active therapy.

Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.

Cancer is independently associated with mortality in patients admitted to the hospital due to coronavirus disease 2019 (COVID-19) infection.

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.

The safety and efficacy of ramucirumab administered after a frontline, non–sorafenib-based systemic therapy in hepatocellular carcinoma was consistent with data from the sorafenib-receiving intention-to-treat population of the phase 3 REACH-2 study.

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

Priyanka Sharma, MD, discusses how data from early clinical studies suggest a role for CDK4/6 inhibitor-based combinations in hormone receptor- positive, HER2-positive breast cancer and triple-negative breast cancer.

Technological advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays.

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

As precision medicine evolves in oncology, companion diagnostics are broadly and increasingly being adopted to guide treatment decisions, enabling clinicians to better and more precisely direct patients to therapies that best suit their unique genomic profiles.